A clinical endocrinological quantitative study of specific symptomatic features among global type ii diabetic patients and a pharmacogenomic analysis of anti-diabetic pharmacotherapeutic agents
Introduction: The heterogeneity of type II diabetes mellitus manifestations depends on the subgroups of diabetes, the clinical variables, disease progression, genetic makeup and lifestyle factors; and this determines the response to treatment with novel glucose-lowering drugs, and lifestyle modifications
Objectives: The objective of this study is a clinical endocrinological quantitative analysis of specific symptomatic features among global type II diabetic patients, and a pharmacogenomic analysis of anti-diabetic pharmacotherapeutic agents.